Thrombosis prevention trial: Compliance with warfarin treatment and investigation of a retained effect

Archives of Internal Medicine

Volumn 163, Issue 12, 2003, Pages 1454-1460

  Rudnicka, Alicja R ^a   Ashby, Deborah ^a   Brennan, Patrick ^a   Meade, Tom ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PLACEBO; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG UTILIZATION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INTERNATIONAL STANDARD UNIT; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL TIME; THROMBOSIS PREVENTION;

ANTICOAGULANTS; ASPIRIN; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; WARFARIN;

EID: 0038001477     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.12.1454     Document Type: Article

References (8)

1. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233-241.
2. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
3. Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation. 2000;102:157-165.
4. Knottenbelt C, Brennan PJ, Meade TW. Antithrombotic treatment and the incidence of angina pectoris. Arch Intern Med. 2002;162:881-886.
5. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
6. Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using a rank preserving structural failure time model. Comm Stat A. 1991;20:2609-2631.
7. Korhonen PA, Laird NM, Palmgren J. Correcting for non-compliance in randomized trials: an application to the ATBC study. Stat Med. 1999;18:2879-2897.
8. Born GVR. Effects of aspirin and warfarin on fatal and non-fatal heart attacks [letter]. Lancet. 1999;354:1472.